CEA BASED VACCINE THERAPY OF CEA BEARING TUMORS

描述(申请人的描述) 本提案中的工作将建立在我们早期的翻译经验的基础上 在癌症疫苗治疗方面，希望改善临床 结果超过了最初的人体试验结果，以扩大我们的证据 癌症疫苗疗法能够刺激免疫系统 识别和杀死人类的癌细胞，并更好地了解如何最好地 监测癌症患者的免疫反应。具体目标是： (1)确定基于增强的最佳给药时间表 两种CEA靶向疫苗的T细胞活性增强 CEA阳性癌症患者的抗肿瘤免疫反应； 确定GM-CSF和/或IL-2在进一步增强T细胞中的作用 中国人群CEA靶向疫苗免疫后的免疫应答 携带CEA的癌症患者；(3)确定肿瘤负担 在患者对这两种CEA靶向的免疫反应中起作用 通过比较没有证据的患者的T细胞反应来接种疫苗 对那些有放射学明显疾病的人，以及(4)记录 是否有证据表明晚期癌症患者具有抗肿瘤活性 确定响应之间是否存在关联(如果看到响应) 免疫增强程度。

DESCRIPTION (Applicant's Description) The work in this proposal will build on our early translational experience in cancer vaccine therapeutics in the hopes of improving the clinical results over those from the initial human trial, to expand our evidence that cancer vaccine therapies are able to stimulate the immune system to recognize and kill cancer cells in humans, and to better understand how best to monitor the immune response in cancer patients. The specific aims are: (1) to determine the optimum administration schedule based on enhancement of T-cell activity of two CEA-targeting vaccines to generate an enhanced anti-tumor immune response in patients with CEA-bearing cancers; (2) to determine the role of GM-CSF and/or IL-2 in further enhancing the T-cell immune response following vaccination with CEA-targeting vaccines in patients with CEA-bearing cancers; (3) to determine whether tumor burden plays a role in a patient's immunologic response to these two CEA-targeting vaccines by comparing the T-cell response of patients without evidence of disease to those with radiographically evident disease, and (4) to document any evidence of anti-tumor activity in patients with advanced cancer and determine if a correlation exists between response (if responses are seen) and degree of immunologic enhancement.